Despite the limited number of patients, our data indicates that IFN-α treated CML patients in remission have increased numbers of NK-cells and clonal γδ+ T-cells and a unique plasma cytokine profile. Here, IFNA1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.